Verici Dx (Verici Dx) Short-Term Debt : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Short-Term Debt?

Verici Dx's Short-Term Debt for the quarter that ended in Jun. 2023 was $0.00 Mil.

Verici Dx's annual Short-Term Debt declined from Dec. 2020 ($0.07 Mil) to Dec. 2021 ($0.00 Mil) but then stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

Verici Dx Short-Term Debt Historical Data

The historical data trend for Verici Dx's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Short-Term Debt Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Short-Term Debt

0.07

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Short-Term Debt	-	-	-	-	-

Verici Dx Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Verici Dx Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Verici Dx's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines